The FDA Approved Pfizer and BioNTech's New COVID Shot. Both Stocks Barely Moved — and That's the Point

On August 27 the FDA cleared Comirnaty XFG, the latest seasonal COVID-19 vaccine from Pfizer and BioNTech, and approved rival updated shots from Moderna and Novavax as well. Doses begin shipping immediately, bound for pharmacy freezers ahead of the fall respiratory season. On the news, shares of both Pfizer and BioNTech traded down about 1%.

Three years ago, an FDA vaccine approval could move billions of dollars of market value in a single day. Today it drew a shrug from both stocks. The bulls see the approval as proof that COVID vaccination is now a permanent, annual category — recurring revenue, the way the flu shot is recurring. The bears see a shrinking, three-competitor market with a narrower label and weak demand. Both camps are looking at the same approval. The fight is over what it's worth at $28 a share for Pfizer and $111 for BioNTech — and the answer is different for each. Today's one-line reaction suggests the market already knew.

Shared facts

As of August 27, 2026:

• Pfizer (PFE): $28.02 a share; about $160 billion market cap; roughly $51.5 billion net debt; about 13.6 times expected earnings; a 6.1% dividend yield; 34 consecutive years of dividend payments; trailing free cash flow near $11 billion.
• BioNTech (BNTX): $111.40 a share; about $28 billion market cap; roughly €16.6 billion of cash, equivalents, and securities on the June 30 balance sheet — call it $16.5 billion net of debt; negative trailing earnings, priced near 9 times sales.
• The approval: Comirnaty XFG cleared for adults 65 and older and for people ages 5 through 64 with a condition that raises the risk of severe illness. Moderna and Novavax also received approvals for their updated shots.
• Recent results:Pfizer's second-quarter revenue rose 3% to $15.0 billion and management raised the midpoint of full-year 2026 revenue guidance. BioNTech's second-quarter revenue fell about 60% to €105.6 million, and management cut 2026 guidance to €1.6–1.9 billion from €2.0–2.3 billion.

Round 1 — What the approval actually changed

Bull's best punch: This is now an institutionalized seasonal decision, not an emergency. The FDA's advisory panel voted 8–1 in May to select this season's strain, turning the COVID shot into something closer to the flu shot — a yearly renewal, insurer-covered, backed by regulators on both sides of the Atlantic (the European Commission cleared the same formula in July). More than five billion Comirnaty doses have been distributed globally since the start. The franchise is not dying; it is settling into a rhythm.

Bear's answer: Read the label. The FDA approved this shot for people 65 and older plus higher-risk younger patients — not the universal 6-months-and-up campaign of earlier years. Uptake has collapsed: in a CDC-supported study covering last season, only about 12% of the uninfected control group had received the prior-year shot, and demand is now concentrated in the old and the medically vulnerable. Three manufacturers split that thinner pie. And governments are drawing down stockpiles instead of reordering — Germany's inventory decision was the stated reason BioNTech cut its revenue forecast. Even their joint COVID trial was paused over enrollment shortfalls.

Round score: bear, narrowly. The bull wins that the category is permanent. The bear wins that permanent and small are not the same thing — and small is the direction of travel.

Round 2 — Same headline, two very different wagers

Now make both stories pay rent, because the approval lands on two companies at completely different moments.

Pfizer: the vaccine is one fading line inside a diversified business. The company just grew total revenue 3% in the second quarter and raised its full-year guidance on the strength of the rest of the portfolio; Pfizer has been cutting costs steadily as the COVID windfall shrank. At 13.6 times expected earnings and a 6.1% yield, the market prices Pfizer as a slow-growing dividend machine whose payout is covered by roughly $11 billion of trailing free cash flow. For this stock, the FDA approval is a rounding error. The bet is everything outside the vaccine.

BioNTech: the vaccine is nearly all the revenue — €223.7 million earned in the entire first half of 2026 — and that revenue is running 50% to 60% below last year's levels while research spending climbs past €1.1 billion in a single half-year. Here is the number that matters. Subtract the cash: from a $28 billion market cap, take out roughly $16.5 billion of net cash, and the market is charging about $11.5 billion of enterprise value for the entire operating company — the shrinking vaccine franchise plus an oncology pipeline that started six pivotal trials in the first half of 2026 — five across pumitamig and one for an antibody-drug conjugate — with a late-stage readout also pending in gotistobart. In plain terms, the market is already valuing the COVID franchise at close to zero and paying for the pipeline. The approval's real job at BioNTech is not revenue. It is runway — keeping the cash machine alive while the oncology bet plays out.

Valuation round — What the price already demands

Lay both stories on the same bar and the duel collapses into one observation: neither stock is priced on the vaccine.

For BioNTech, the bull's "durable floor" argument only matters if the franchise is worth a meaningful slice of a $28 billion market cap. It is not — the $11.5 billion enterprise value bundles the leftover vaccine franchise together with six oncology programs, so the market has already conceded the bear's shrinkage point. For Pfizer, add or subtract a few hundred million dollars of seasonal COVID revenue and a 13.6-times-forward multiple barely twitches. Both prices behave as though the COVID franchise is a tail, because in both cases it largely is. On this headline, the two camps cancel out: neither the durable-floor bull nor the shrinking-market bear can point to a claim the current price has not already taken.

Ruling

No edge from this approval at today's prices. The franchise is real but small, and both stocks already price it that way. This is a maintenance event — it keeps BioNTech's runway funded and costs Pfizer almost nothing — not a catalyst for either share price.

If you are weighing the two stocks for reasons that go beyond this headline: Pfizer is a yield story whose dividend depends on the diversified base growing into a $51.5 billion net-debt load; BioNTech is a cash-protected pipeline bet where the question is whether late-stage oncology data can justify an enterprise value the market is already paying in advance. Neither should be bought because the FDA said yes.

The burden of proof sits with the bulls, and the tripwires are dated. For BioNTech, watch the next quarterly print — the one where €613 million of Bristol-Myers milestone revenue is expected to land — and then this autumn's 2027 government order books. Any result below the €1.6–1.9 billion guided range means the franchise is fading faster than the cash cushion assumes; a positive Phase 3 readout on pumitamig or gotistobart before year-end makes the vaccine debate moot. For Pfizer, watch the next guidance print and whether the combined portfolio keeps the 6% dividend covered by free cash flow. A dividend cut — the thing every 13.6-times-forward buyer is implicitly betting against — is the event that breaks the yield thesis.

The next evidence event is BioNTech's third-quarter earnings, not another FDA decision. By the time this season's shots reach pharmacy freezers in September, the only questions that will have mattered are each company's non-COVID ones — Pfizer's pipeline and its payout, BioNTech's oncology data. Today's approval settled none of them.